Advancing Precision Oncology and RAS-Targeted Therapies. For decades, RAS mutations (like KRAS) were considered "undruggable" targets in oncology. Daraxonrasib represents a new frontier.
It is a targeted inhibitor that binds to specific mutant forms of the RAS protein, effectively blocking the signaling pathways that tell cancer cells to grow and divide.
This Phase III clinical trial is evaluating the efficacy and safety of Daraxonrasib in patients with advanced solid tumors, including pancreatic and colorectal cancers.
| Key Efficacy Outcomes Monitored | Description |
|---|---|
| Overall Survival (OS) | The length of time patients live after starting the treatment. |
| Progression-Free Survival (PFS) | The length of time during and after treatment that a patient lives with the disease without it getting worse. |